Nebulised granulocyte-macrophage colony-stimulating factor (GM-CSF) in autoimmune pulmonary alveolar proteinosis: a systematic review and meta-analysis.
Journal
European respiratory review : an official journal of the European Respiratory Society
ISSN: 1600-0617
Titre abrégé: Eur Respir Rev
Pays: England
ID NLM: 9111391
Informations de publication
Date de publication:
31 Dec 2023
31 Dec 2023
Historique:
received:
19
04
2023
accepted:
29
08
2023
medline:
24
11
2023
pubmed:
23
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
Autoimmune pulmonary alveolar proteinosis (aPAP) results from impaired macrophage-mediated clearance of alveolar surfactant lipoproteins. Whole lung lavage has been the first-line treatment but recent reports suggest the efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF). We aimed to review the efficacy and safety of nebulised GM-CSF in aPAP. We conducted a systematic review and meta-analysis searching Embase, CINAHL, MEDLINE and Cochrane Collaborative databases (1946-1 April 2022). Studies included patients aged >18 years with aPAP receiving nebulised GM-CSF treatment and a comparator cohort. Exclusion criteria included secondary or congenital pulmonary alveolar proteinosis, GM-CSF allergy, active infection or other serious medical conditions. The protocol was prospectively registered with PROSPERO (CRD42021231328). Outcomes assessed were St George's Respiratory Questionnaire (SGRQ), 6-min walk test (6MWT), gas exchange (diffusing capacity of the lung for carbon monoxide ( Six studies were identified for review and three for meta-analysis, revealing that SGRQ score (mean difference -8.09, 95% CI -11.88- -4.3, p<0.0001), functional capacity (6MWT) (mean difference 21.72 m, 95% CI -2.76-46.19 m, p=0.08), gas diffusion ( Patients with aPAP treated with inhaled GM-CSF demonstrated significant improvements in symptoms, dyspnoea scores, lung function, gas exchange and radiology indices after treatment with nebulised GM-CSF of varying duration. There is an important need to review comparative effectiveness and patient choice in key clinical outcomes between the current standard of care, whole lung lavage, with the noninvasive treatment of nebulised GM-CSF in aPAP.
Sections du résumé
BACKGROUND
BACKGROUND
Autoimmune pulmonary alveolar proteinosis (aPAP) results from impaired macrophage-mediated clearance of alveolar surfactant lipoproteins. Whole lung lavage has been the first-line treatment but recent reports suggest the efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF). We aimed to review the efficacy and safety of nebulised GM-CSF in aPAP.
METHODS
METHODS
We conducted a systematic review and meta-analysis searching Embase, CINAHL, MEDLINE and Cochrane Collaborative databases (1946-1 April 2022). Studies included patients aged >18 years with aPAP receiving nebulised GM-CSF treatment and a comparator cohort. Exclusion criteria included secondary or congenital pulmonary alveolar proteinosis, GM-CSF allergy, active infection or other serious medical conditions. The protocol was prospectively registered with PROSPERO (CRD42021231328). Outcomes assessed were St George's Respiratory Questionnaire (SGRQ), 6-min walk test (6MWT), gas exchange (diffusing capacity of the lung for carbon monoxide (
RESULTS
RESULTS
Six studies were identified for review and three for meta-analysis, revealing that SGRQ score (mean difference -8.09, 95% CI -11.88- -4.3, p<0.0001), functional capacity (6MWT) (mean difference 21.72 m, 95% CI -2.76-46.19 m, p=0.08), gas diffusion (
CONCLUSIONS
CONCLUSIONS
Patients with aPAP treated with inhaled GM-CSF demonstrated significant improvements in symptoms, dyspnoea scores, lung function, gas exchange and radiology indices after treatment with nebulised GM-CSF of varying duration. There is an important need to review comparative effectiveness and patient choice in key clinical outcomes between the current standard of care, whole lung lavage, with the noninvasive treatment of nebulised GM-CSF in aPAP.
Identifiants
pubmed: 37993127
pii: 32/170/230080
doi: 10.1183/16000617.0080-2023
pmc: PMC10663936
pii:
doi:
Substances chimiques
Granulocyte-Macrophage Colony-Stimulating Factor
83869-56-1
Oxygen
S88TT14065
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflict of interest: All authors have nothing to disclose.
Références
N Engl J Med. 2019 Sep 5;381(10):923-932
pubmed: 31483963
J Cyst Fibros. 2011 Jan;10(1):9-14
pubmed: 20884302
Am J Respir Crit Care Med. 2022 May 1;205(9):1016-1035
pubmed: 35227171
Am J Ther. 2016 Nov/Dec;23(6):e1671-e1679
pubmed: 26039225
Eur Respir J. 2009 Jun;33(6):1503-6
pubmed: 19483052
Clin Drug Investig. 2014 Aug;34(8):553-64
pubmed: 24890235
Chest. 1970 Oct;58(4):326-32
pubmed: 4096977
Eur Respir J. 1999 Aug;14(2):383-9
pubmed: 10515418
COPD. 2015 Feb;12(1):31-7
pubmed: 24915470
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Chest. 2006 Jul;130(1):227-37
pubmed: 16840407
COPD. 2015 Jun;12(3):240-8
pubmed: 25208266
Ann Am Thorac Soc. 2017 Aug;14(8):1298-1304
pubmed: 28421817
Am J Respir Crit Care Med. 2001 Feb;163(2):524-31
pubmed: 11179134
Curr Opin Pulm Med. 2019 Sep;25(5):450-458
pubmed: 31365379
Orphanet J Rare Dis. 2020 Jul 2;15(1):174
pubmed: 32615994
Nat Rev Dis Primers. 2019 Mar 7;5(1):16
pubmed: 30846703
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
N Engl J Med. 1958 Jun 5;258(23):1123-42
pubmed: 13552931
Lancet Respir Med. 2018 Jul;6(7):e35
pubmed: 29580708
J Thorac Dis. 2017 Jun;9(6):1697-1706
pubmed: 28740686
Lancet Respir Med. 2018 Jul;6(7):554-565
pubmed: 29397349
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Orphanet J Rare Dis. 2013 Apr 04;8:53
pubmed: 23557396
COPD. 2005 Mar;2(1):75-9
pubmed: 17136966
Respirology. 2006 Jan;11 Suppl:S16-22
pubmed: 16423263
N Engl J Med. 2009 Dec 31;361(27):2679-81
pubmed: 20042763
Respir Med. 2012 Feb;106(2):284-93
pubmed: 22112784
Eur Respir J. 2006 Mar;27(3):585-93
pubmed: 16507860
Am Rev Respir Dis. 1992 Jun;145(6):1321-7
pubmed: 1595997
N Engl J Med. 2020 Oct 22;383(17):1635-1644
pubmed: 32897035
Lung. 2015 Apr;193(2):209-11
pubmed: 25557091
J Cyst Fibros. 2009 Sep;8(5):332-7
pubmed: 19651542
Treat Respir Med. 2004;3(4):229-34
pubmed: 15350161
Zhonghua Yi Xue Za Zhi. 2015 Sep 8;95(34):2766-70
pubmed: 26711974
Am J Respir Crit Care Med. 2005 May 15;171(10):1142-9
pubmed: 15735059
J Clin Epidemiol. 2003 Dec;56(12):1170-6
pubmed: 14680667
Am J Respir Crit Care Med. 2010 Jun 15;181(12):1345-54
pubmed: 20167854
Arch Phys Med Rehabil. 2010 Feb;91(2):221-5
pubmed: 20159125
Am J Respir Crit Care Med. 2010 Jul 1;182(1):49-61
pubmed: 20224064